Skip to content
NBDC Human Database

No datasets in the cart.

Go to the cart

Due to system maintenance, the application system, application review by the Data Access Committee will be unavailable during the following period.
Schedule: October 5th (Mon), 2026, 9:00 - October 7th (Wed), 2026, 15:00 (JST)
We apologize for any inconvenience this may cause and appreciate your understanding.

We are currently receiving a large number of applications for data submission, and the review process is taking longer than usual.We sincerely apologize for the delay and kindly ask for your understanding. When submitting an application, we would greatly appreciate it if you could allow sufficient time for the processing.

Following a change to our organizational structure effective April 1, 2026, this division has been renamed from the "Database Center for Life Science, Joint Support-Center for Data Science Research" to the "Database Division for Life Science (DBCLS), BioData Science Initiative (BSI), National Institute of Genetics (NIG)". Where the former name still appears in the guidelines, please read it as the new name.

Research ID

hum0404-v1Release info

Latest

Research title

Elucidation of pathology and therapeutic development using genome analysis, iPS cells, and genome editing for cardiovascular diseases / Elucidation of pathology and development of novel medical technology using iPS cells derived from patients with cardiovascular disease

Research overview

Aims
In this study, we analyze the genomic information of samples from patients with various cardiovascular diseases, including severe heart failure, and identify genetic mutations and polymorphisms that are thought to be related to the pathology of cardiovascular diseases. The purpose is to elucidate the underlying mechanism and develop new therapeutic interventions. The source of the genome to be analyzed is mainly peripheral blood, but in some cases, the genome extracted from the myocardial tissue obtained by myocardial biopsy or iPS cells generated from the patient is also used. In the analysis using iPS cells, we repair genetic mutation using genome editing technology such as CRISPR/Cas9 and analyze the pathological phenotypes.
Methods
[scRNA-seq] GFP (Control) or S-RBD-sfGFP was added to iPS cell-derived cardiomyocytes and after 48 hours the cells were collected and single-cell RNA sequence analysis was performed.
[WGS] Genomic DNA was extracted from the peripheral blood cells of cardiomyopathy cases and performed whole genome sequencing analysis.
Participants/materials
iPS cell-derived cardiomyocytes established from a cardiomyopathy case, peripheral blood cells of 3 cardiomyopathy cases
URL

Datasets

CartDataset IDType of dataAnalysis methodAccess criteriaDate published
JGAD000749NGS (scRNA-seq)
  • scRNA-seq
Controlled-access (Type I)2025-10-01
E-GEAD-628NGS (scRNA-seq)
  • scRNA-seq
Unrestricted-access2023-12-06
JGAD000837NGS (WGS)
  • WGS
Controlled-access (Type I)2025-10-01
JGAD000838NGS (WGS)
  • WGS
Controlled-access (Type I)2025-10-01
JGAD000839NGS (WGS)
  • WGS
Controlled-access (Type I)2025-10-01

Data provider

Principal investigator
Shuichiro Higo
Affiliation
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine

Research projects

No research projects.

Grants

No grants.

Related publications

TitleDOIDataset ID
SARS-CoV-2 spike receptor-binding domain is internalized and promotes protein ISGylation in human induced pluripotent stem cell-derived cardiomyocytes
https://doi.org/10.1038/s41598-023-48084-7 (opens in a new tab)

Controlled access users

No use of the controlled access data has been recorded.